- Home
- / Chimeric Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Chimeric Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-04
Market Capitalization
$12.7 M
2024-10-04
Revenue
$4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| AUD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.0M | |||||
| Cost of goods sold | 847.0K | |||||
| Gross profit | 2.6M | 4.5M | 9.6M | 11.7M | ||
| Gross profit margin, % | 295.9% | |||||
| Operating expense total | 64.0K | 14.8M | 17.2M | 29.5M | 20.6M | 21.9M |
| Depreciation and amortization | 3.0K | 8.0K | 8.0K | 4.0K | ||
| EBITDA | (64.0K) | (14.8M) | (14.6M) | (25.0M) | (11.0M) | (10.1M) |
| EBITDA margin, % | -255.3% | |||||
| EBIT | (64.0K) | (14.8M) | (14.6M) | (25.1M) | (12.4M) | (10.0M) |
| EBIT margin, % | -253.0% | |||||
| Interest income | 3.0K | 13.0K | 27.0K | 121.0K | 48.0K | |
| Interest expense | 6.0K | 640.0K | 773.0K | 332.0K | 211.0K | |
| Pre tax profit | (64.0K) | (15.1M) | (15.7M) | (25.8M) | (12.5M) | (10.3M) |
| Income tax expense | 163.0K | 93.0K | 10.0K | 111.0K | ||
| Net Income | (64.0K) | (15.1M) | (15.9M) | (25.9M) | (12.5M) | (10.4M) |